Newsbenzinga
BioCryst Shifts Pipeline Strategy, Reaffirms Sales Outlook Of $635.00M-$660.00M Vs 670.47M
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…